LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.

Our Leadership

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025

Earnings Release PDF

10-Q PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Latest News

Jul 31, 2025 • 4:05 PM EDT

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

View Press Release View All News

Recent Event

Aug 1, 2025 8:00 am EDT

LENZ Therapeutics FDA Approval Conference Call

View Event View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449